SCD and metabolic dysfunction-associated steatotic liver disease: Collectively, the results of this study provide the first demonstration that inhibition of SCD1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy, suggesting the novel function of SCD1 in hepatic lipogenesis and that the SCD1-AMPK-lipophagy pathway may be a potential therapeutic target for NAFLD.